Eli Lilly's performance in the biopharmaceutical sector reflects its strong market position, despite facing challenges. The ...
Eli Lilly and Company is unveiling its new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, which will be available ...
Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results